.svg?dpl=dpl_BtqbaxWLeJDnEPkWAbWMgJ45Wsnb){kind=small}
%20copy.webp&w=3840&q=75&dpl=dpl_BtqbaxWLeJDnEPkWAbWMgJ45Wsnb)
Selected Work · 2020–2026
Portfolio
Live data visualizations, fluid simulations, full-stack portals, polished marketing sites, and the corporate decks behind them. Everything here was designed and engineered in-house.
The work, working.
Every chart, simulation, and dashboard below is the real thing. Live, interactive, and built by us. Hover, click, and scroll through. This is what we ship for biotech clients.
High-end data visualizations
Transform complex assay data into beautiful, interactive charts. We build custom data visualizations that highlight key findings with premium styling, brand color systems, and motion that makes the numbers feel inevitable.
Synergy in action
Source: Jurkat T-Cells, 48 hr
Variance collapses
High-Sensitivity Multiplex Array
52 weeks. One curve below the other.
Mean reduction
0%
Responders (≥20%)
0%
Significance
p<0.001
95% CI bands · investigational data
WebGL, particles, and scientific simulation
When the brief calls for it, we build Canvas and WebGL backdrops that capture the physical energy of your science: molecular fields, CFD particle simulations of microfluidic devices, fluidic mixers, and convergence diagrams that move in real time.
First impressions
engineered to captivate.
We combine high-end 3D renders with custom WebGL particle systems to create dynamic, living backgrounds that immediately establish your scientific credibility.
The Convergence Model
Scroll the page. The diagram tracks your position, highlights the relevant chapter, and animates particles along the connection that matches, keeping your narrative perfectly synced to the visual.
Discovery Phase Integration
Highlighting early-stage pipeline assets, proprietary screening platforms, and the science that started the story.
Clinical Translation
Mapping the journey from bench to bedside with clear milestone tracking, biomarker dashboards, and clean trial visuals.
Commercial Readiness
Demonstrating market potential, partnerships, and go-to-market. The moment your science meets its audience.
Nanoparticle formulation dynamics
Computational Fluid Dynamics
Real-time Navier-Stokes approximation visualizing flow around parametric CAD geometries. Used for microfluidic device optimization and nanoparticle formulation scaling.
Animated clinical pipeline interfaces
Show stakeholders exactly where each program stands. Continuous-flow liquid metaphors, phase-tracking horizontal bars, and interactive program drill-downs, designed to make complex portfolios click instantly.
Programs in motion
Lymphedema
Phase II — enrolling
Lipedema
Phase II — dose ranging
Lymphatic Targeting
Preclinical exploration
Topical Delivery
Formulation studies
Continuous-flow visualization
Registrational Study
Combination with pembrolizumab
Neoadjuvant resectable melanoma patients
Ruxotemitide (LTX-315)
Registrational Study - Neoadjuvant Melanoma
Ruxotemitide is an oncolytic peptide that has consistently delivered strong tumor activity, excellent tolerability and clear systemic immune engagement in Phase 2 trials. As a monotherapy, ruxotemitide enables rapid tumor destruction, robust immune cell infiltration and complete regression in injected tumors. Ruxotemitide also delivers abscopal effects in distant metastases, demonstrating clear systemic immune activation.
In combination with immune checkpoint inhibitors, ruxotemitide affords disease control in patients who had previously failed immune checkpoint inhibitor therapy, indicating the impact ruxotemitide can have on the current standard of care for many cancers in the neoadjuvant setting.
Monotherapy
Basal cell carcinoma
Ruxotemitide (LTX-315)
Monotherapy - Basal Cell Carcinoma
Verrica Pharmaceuticals has generated impressive Phase 2 data in basal cell carcinoma with ruxotemitide as a monotherapy. They have reported a 51% complete response rate, and clinical responses in 97% of the patients with significant reduction of tumor size.
Additionally, Verrica has demonstrated that ruxotemitide reprograms the tumor microenvironment, with patient biopsies showing significant increases in CD4+, CD8+ T cells, and B-cells, indicating strong recruitment of effector immune populations into the tumor.
NeoLIPA
Investigator-initiated study
Neoadjuvant resectable melanoma patients
Ruxotemitide (LTX-315)
NeoLIPA Study
Ruxotemitide is currently being evaluated in an investigator-initiated Phase 2 study 'NeoLIPA' in patients with resectable melanoma prior to surgery. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDA®).
The objective of this study is to demonstrate that ruxotemitide improves outcomes in these patients and prevents disease recurrence.
Mono-and combination therapy
Solid tumors (deep seated lesions)
LTX-401
Deep-Seated Solid Tumors
LTX-401 is an oncolytic molecule designed for deep-seated tumors.
LTX-401 expands our oncolytic molecule platform into deep-seated tumors through image-guided intratumoral delivery. This opens access to the liver and other internal tumors where intratumoral treatment has historically not been feasible.
LTX-401 has demonstrated strong proof-of-concept in multiple difficult-to-treat cancer models, including curing animals of liver cancer, and is currently in last-stage pre-clinical development.
Full-stack portals, dashboards, and commerce
We don't stop at marketing sites. Investor-relations widgets with live tickers, secure client portals for trial management, e-commerce flows tailored for cold-chain biotech logistics. Production software, designed and engineered end-to-end.
BIOTX Therapeutics Inc
2026-05-10 · 09:30 ET
Change
+$0.00
High / Low
0.00 / 0.00
Volume
0
Turnover
$0K
Ticker
BIOTX
ISIN
US0010405780
Market
NASDAQ
Sector
Biotech
Shares
76.9M
Mkt Cap
$834.4M
Dr. Sarah Jenkins
Principal Investigator
Cart / 0 items
Temperature-sensitive products ship via specialized cold-chain logistics.
Need help? Our scientists can advise on product selection. Contact us →